Table 3.

Detailed information on FG reports.

	Canagliflozin (n)	Dapagliflozin (n)	Empagliflozin (n)	Ertugliflozin (n)	Total (n, %)
Age of patient
<18	1	1	0	0
18-64	148	55	100	2
>64	25	14	47	0
Average (years)	56	57	57	51
Gender of patient
Male	130 (65.33%)	69 (63.89%)	146 (63.20%)	3 (100.00%)
Female	58 (29.15%)	29 (26.85%)	64 (27.71%)	0 (-)
Unknown	11 (5.53%)	10 (9.26%)	21 (9.09%)	0 (-)
Average weight of patient (kg)	98	112	109	180
Reporter
Healthcare professionals	53	73	191	2	319 (58.86%)
Consumers	144	8	40	1	193 (35.61%)
Unknown	2	27	1	0	30 (5.54%)
Reported year
2019	153	68	183	3	407 (75.09%)
2018	31	27	45	0	103 (19.00%)
2017	2	1	1	0	4 (0.74%)
2016	2	7	1	0	10 (1.85%)
2015	10	4	1	0	15 (2.77%)
2014	0	1	0	0	1 (0.18%)
Unknown	1	0	1	0	2 (0.36%)
Area
North America	178	51	127	2	358 (66.05%)
Europe	17	40	65	0	122 (22.51%)
Asian	4	11	21	0	36 (6.64%)
Oceania	0	2	13	1	16 (2.95%)
South America	0	4	4	0	8 (1.48%)
Africa	0	0	1	0	1 (0.18%)
Unknown	0	0	1	0	1 (0.18%)
Outcome events (n, %)
Hospitalization-initial or prolonged	172 (86.43%)	76 (72.38%)	141 (72.38%)	2 (66.67%)
Other serious (important medical event)	55 (27.64%)	54 (51.43%)	133 (51.43%)	1 (33.33%)
Life-threatening	30 (15.08%)	24 (22.86%)	50 (22.86%)	0 (0.00)
Disability	28 (14.07%)	8 (7.62%)	19 (7.62%)	0 (0.00)
Death	7 (3.52%)	7 (6.67%)	12 (5.29%)	0 (0.00)
Required intervention to prevent permanent impairment/damage	3 (1.51%)	0 (0.00)	4 (1.76%)	0 (0.00)
Total report number	199	105	227	3

Note: no reports of ipragliflozin, luseogliflozin, or tofogliflozin.